ArticleAmerican journal of respiratory cell and molecular biology2013
Foxa2 regulates leukotrienes to inhibit Th2-mediated pulmonary inflammation.
Article in American journal of respiratory cell and molecular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- The FOXA transcription factors in allergic airway disease and asthma.Frontiers in allergy · 2026Review
- ACE-2 blockade and TMPRSS2 inhibition mitigate SARS-CoV-2 severity following cigarette smoke exposure in airway epithelial cellsMolecular therapy. Nucleic acids · 2025Article
- Epithelial-immune interactions govern type 2 immunity at barrier surfaces.Current opinion in immunology · 2024Review
- Epigenetic Approaches to Identifying Asthma Endotypes.Allergy, asthma & immunology research · 2024Review
- FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma.The Journal of biological chemistry · 2024Article
- Allergic airway recall responses require IL-9 from resident memory CD4Science immunology · 2022Article
- BMAL1/FOXA2-induced rhythmic fluctuations in IL-6 contribute to nocturnal asthma attacks.Frontiers in immunology · 2022Article
- The Pioneer Transcription Factor Foxa2 Modulates T Helper Differentiation to Reduce Mouse Allergic Airway Disease.Frontiers in immunology · 2022Article
- Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FOXA2-phosphatase signaling.Mucosal immunology · 2020Article
- DNA Methylation: A Potential Biomarker of Chronic Obstructive Pulmonary Disease.Frontiers in cell and developmental biology · 2020Review
- An Elusive Fox that Suppresses Scgb1a1 in Asthma Has Been Found.American journal of respiratory cell and molecular biology · 2019Article
- HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.The Journal of clinical investigation · 2019Article
- Article
- Cigarette smoke and HIV synergistically affect lung pathology in cynomolgus macaques.The Journal of clinical investigation · 2018Article
- Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease.American journal of respiratory and critical care medicine · 2017Article
- Innate Immunity to Respiratory Infection in Early Life.Frontiers in immunology · 2017Review
- Aberrant DNA methylation and expression of SPDEF and FOXA2 in airway epithelium of patients with COPD.Clinical epigenetics · 2017Article
- Forkhead box protein A2 and T helper type 2-mediated pulmonary inflammation.World journal of methodology · 2015Review
- Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.EMBO molecular medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
Foxa2 is a member of the Forkhead family of nuclear transcription factors that is highly expressed in respiratory epithelial cells of the developing and mature lung. Foxa2 is required for normal airway epithelial differentiation, and its deletion causes goblet-cell metaplasia and Th2-mediated pulmonary inflammation during postnatal development. Foxa2 expression is inhibited during aeroallergen sensitization and after stimulation with Th2 cytokines, when its loss is associated with goblet-cell metaplasia. Mechanisms by which Foxa2 controls airway epithelial differentiation and Th2 immunity are incompletely known. During the first 2 weeks after birth, the loss of Foxa2 increases the production of leukotrienes (LTs) and Th2 cytokines in the lungs of Foxa2 gene-targeted mice. Foxa2 expression inhibited 15-lipoxygenase (Alox15) and increased Alox5 transcription, each encoding key lipoxygenases associated with asthma. The inhibition of the cysteinyl LT (CysLT) signaling pathway by montelukast inhibited IL-4, IL-5, eotaxin-2, and regulated upon activation normal T cell expressed and presumably secreted expression in the developing lungs of Foxa2 gene-targeted mice. Montelukast inhibited the expression of genes regulating mucus metaplasia, including Spdef, Muc5ac, Foxa3, and Arg2. Foxa2 plays a cell-autonomous role in the respiratory epithelium, and is required for the suppression of Th2 immunity and mucus metaplasia in the developing lung in a process determined in part by its regulation of the CysLT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.